The KPCXM18 not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 12±2 days.”In the company’s words, NCT07279493 on ClinicalTrials.gov
- Tested for
- Acute Ischemic Stroke
- Main trialPhase 2
- “This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.”In the company’s words, NCT07279493 on ClinicalTrials.gov
Other drugs for Acute Ischemic Stroke
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- DM199DiaMedica Therapeutics Inc · Phase 2/3
- SP-8203Shin Poong Pharmaceutical Co. Ltd. · Phase 3
- SHPL-49Shanghai Hutchison Pharmaceuticals Limited · Phase 3
- RhTNK-tPACSPC · Phase 3
- SovateltidePharmazz, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 18 Oct 2026 | Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke | |
| Phase 2Unknown | 1 May 2024 | Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026